Related references
Note: Only part of the references are listed.Salinomycin Selectively Targets 'CD133+' Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines
Tao-Tao Dong et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein
Ju-Hwa Kim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3
Li Ma et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2010)
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells
Dominik Fuchs et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
ErbB2 requires integrin α5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells
Keneshia K. Haenssen et al.
JOURNAL OF CELL SCIENCE (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
A. Roidl et al.
ONCOGENE (2010)
Breast cancer chemoresistance: Emerging importance of cancer stem cells
Suebwong Chuthapisith et al.
SURGICAL ONCOLOGY-OXFORD (2010)
Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells
Florian Reim et al.
CANCER RESEARCH (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins
Hongyan Zhou et al.
CELL STEM CELL (2009)
Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab
Alessandra Magnifico et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments
Mark A. LaBarge et al.
INTEGRATIVE BIOLOGY (2009)
High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability
Alysha K. Croker et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
M. Pickl et al.
ONCOGENE (2009)
Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer
Ulf R. Rapp et al.
PLOS ONE (2009)
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Helen M. Coley
CANCER TREATMENT REVIEWS (2008)
Stemness genomics law governs clinical behavior of human cancer: Implications for decision making in disease management
Gennadi V. Glinsky
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
Ittai Ben-Porath et al.
NATURE GENETICS (2008)
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
H. Korkaya et al.
ONCOGENE (2008)
ABC multidrug transporters: structure, function and role in chemoresistance
Frances J. Sharom
PHARMACOGENOMICS (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells
Matthew J. Grimshaw et al.
BREAST CANCER RESEARCH (2008)
Conformation and location of membrane-bound salinomycin-sodium complex deduced from NMR in isotropic bicelles
Nobuaki Matsumori et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Comparative gene expression analysis of a chronic myelogenous leukemia c-ell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors
Fei Bao et al.
LEUKEMIA RESEARCH (2007)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation
Tiffany M. Phillips et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: Implications for tumor growth, metastasis, and chemoresistance
Lianglin Zhang et al.
CANCER RESEARCH (2006)
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
J Cicenas et al.
EUROPEAN JOURNAL OF CANCER (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
HER-2 testing in breast cancer using parallel tissue-based methods
H Yaziji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis
KRM Shaw et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2004)
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control
HK Weir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
G Dontu et al.
GENES & DEVELOPMENT (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
B Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3
XM Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu):: A study of incidence and correlation with outcome in breast cancer
AD Thor et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Primary systemic therapy in operable breast cancer
AC Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
